Global pharmaceutical giant Bristol-Myers Squibb has signed a licensing agreement for research conducted at UW-Milwaukee that may produce a new anti-anxiety drug. Terms were not disclosed.
Bristol-Myers Squibb signed the licensing agreement with WiSys, the patenting and licensing arm for all of the UW System except UW-Madison. The license involves the research of UW-Milwaukee chemistry professor James Cook, who is developing new classes of drug compounds to treat psychiatric disorders.